Corium to Join NASDAQ Biotechnology Index
“2017 has been a year of important progress for Corium and our lead proprietary once-weekly patch for Alzheimer’s disease, Corplex™ Donepezil,” said
The NASDAQ Biotechnology Index contains securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals that also meet other eligibility criteria. Companies in the NBI must meet certain requirements, including minimum market capitalization and average daily trading volume, among other criteria. The NASDAQ Biotechnology Index is re-ranked annually and forms the basis for a number of Exchange Traded Funds (ETFs), including the
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our proprietary products and product candidates. Forward-looking statements are based on management's current expectations and projections and are subject to risks and uncertainties, which may cause Corium's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect Corium's business and its results are detailed in Corium's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, filed with the Securities and Exchange Commission (
Corplex™ and MicroCor® are registered trademarks of
Investor and Media Contact:
Source: Corium International, Inc.